#USA #Cambridge #DNA Methylation #SuperMethyl Max #Ellis Bio

Ellis Bio Introduces the SuperMethyl™ Max Bisulfite Conversion Kit

In a groundbreaking development for the field of epigenomics, Ellis Bio has officially launched its SuperMethyl™ Max Bisulfite Conversion Kit. This innovative product enables researchers to perform high-accuracy methylation profiling using minuscule amounts of DNA, with as little as 100 picograms needed. The announcement was made during the Advances in Genome Biology and Technology (AGBT) General Meeting, showcasing the company's commitment to advancing genetic research.

The SuperMethyl™ Max kit utilizes a cutting-edge bisulfite chemistry that is notably mild, as highlighted in a study published in Nature Communications. Unlike traditional bisulfite methods, which often lead to significant DNA damage, the SuperMethyl™ Max dramatically reduces such risks, ensuring higher specificity and fewer false positive results compared to enzymatic approaches. This shift is pivotal, especially for researchers focused on substances like circulating cell-free DNA (cfDNA) that are typically more delicate and challenging to analyze.

Enhancing Precision in Low-Input Scenarios

The design of this new kit is particularly advantageous for applications involving liquid biopsies, early cancer diagnostics, and other low-input workflows. With the risk of compromising precious DNA samples minimized, the kit allows for better retention of integrity and increases the reliability of methylation profiling.

Here are some key benefits demonstrated through benchmarking studies:

• - High Specificity: Achieving near-zero false positive and negative results due to a consistently low background signal, even at minimal input levels.
• - Unmatched Efficiency: Users report achieving a staggering 99.8% C-to-U conversion, providing confidence in the accuracy of their methylation results.
• - Preserved DNA Integrity: The method delivers library yields that meet or exceed those of enzyme-based techniques, significantly boosting productivity and research results.
• - Streamlined Workflow: Researchers can complete the protocol in under three hours, substantially reducing time compared to previous methodologies.

The advancements in the SuperMethyl™ Max kit stem from reduced DNA damage during the conversion process. This sophistication results in improved library complexity, benefiting a range of applications including PCR, microarray, and next-generation sequencing techniques.

Real-World Applications and Evaluations

Prior to its commercial launch, the SuperMethyl™ Max kit was available through an early access program, where institutions like the Garvan Institute of Medical Research evaluated its efficacy for PCR-based methylation applications. Such testing has validated the kit's effectiveness and usability across various research contexts.

Research teams from companies like Admera Health also contributed to third-party testing, solidifying confidence in the kit's market-readiness. This collaborative effort highlights the importance of ensuring products meet rigorous scientific standards.

Availability of the SuperMethyl™ Max Kit

Researchers eager to enhance their experimental protocols can now purchase the SuperMethyl™ Max kit directly from the Ellis Bio website. The company has also established partnerships with several distributors across the globe, including PELOBiotech (EU), Stratech Scientific (UK), Eagle Biosciences (US), and AS ONE (Japan) to ensure widespread accessibility of this groundbreaking technology.

About Ellis Bio

Spun out of The University of Chicago, Ellis Bio, Inc. is at the forefront of multi-omic technologies aimed at dissecting the complexities of DNA and RNA. Founded by renowned scientists including Professor Chuan He, Ellis Bio extends its portfolio beyond traditional sequencing, delving into the dynamic modifications of DNA that influence gene expression.

For researchers keen on leveraging the latest innovations in epigenomic analysis, the SuperMethyl™ Max Bisulfite Conversion Kit stands as a robust tool that promises to refine understanding and applications of DNA methylation in various diseases. For those interested in more information, please visit Ellis Bio's website.